N Harbeck

Summary

Affiliation: Klinikum rechts der Isar
Country: Germany

Publications

  1. ncbi request reprint Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
    Julia Dorn
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D 81675 Munich, Germany, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Biol Chem 387:1121-8. 2006
  2. ncbi request reprint Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynaecology, Technical University of Munich, Germany
    Methods Mol Med 120:245-65. 2006
  3. doi request reprint Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients
    Nadia Harbeck
    Department of Obstetrics and Gynecology and Pathology, Technical University of Munich, Munich, Germany
    J Clin Oncol 26:5036-42. 2008
  4. ncbi request reprint Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer
    N Harbeck
    Department of Obstetrics and Gynecology, Technical University, Munich
    Int J Biol Markers 15:79-83. 2000
  5. ncbi request reprint Neural network analysis of follow-up data in primary breast cancer
    N Harbeck
    Department of Obstetrics and Gynecology, Technical University, Munich, Germany
    Int J Biol Markers 15:116-22. 2000
  6. ncbi request reprint Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor
    N Harbeck
    Frauenklinik, Technische Universitat Munchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Onkologie 24:238-44. 2001
  7. ncbi request reprint Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
    N Harbeck
    Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, D 81675 Munich, Germany
    Clin Cancer Res 7:2757-64. 2001
  8. ncbi request reprint Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination
    Nadia Harbeck
    Clinical Research Group, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    J Clin Oncol 20:1000-7. 2002
  9. ncbi request reprint Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
  10. ncbi request reprint [Adjuvant chemotherapy in primary carcinoma of the breast]
    N Harbeck
    Frauenklinik der Technischen Universitat Munchen, Germany
    Zentralbl Gynakol 125:322-6. 2003

Detail Information

Publications114 found, 100 shown here

  1. ncbi request reprint Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
    Julia Dorn
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D 81675 Munich, Germany, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Biol Chem 387:1121-8. 2006
    ..These results support the notion that several tissue kallikreins are co-expressed in ovarian cancer patients, substantiating the existence of a steroid hormone-driven tissue kallikrein cascade in this disease...
  2. ncbi request reprint Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynaecology, Technical University of Munich, Germany
    Methods Mol Med 120:245-65. 2006
    ..Such a technique allows rapid and quantitative determination of uPA and PAI-1, even in small breast cancer specimens...
  3. doi request reprint Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients
    Nadia Harbeck
    Department of Obstetrics and Gynecology and Pathology, Technical University of Munich, Munich, Germany
    J Clin Oncol 26:5036-42. 2008
    ....
  4. ncbi request reprint Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer
    N Harbeck
    Department of Obstetrics and Gynecology, Technical University, Munich
    Int J Biol Markers 15:79-83. 2000
    ..001). In conclusion, tumor-associated PAI-1 and cathepsins D and L provide significant, statistically independent prognostic information for DFS and OS in primary breast cancer, even after a median follow-up period of almost 10 years...
  5. ncbi request reprint Neural network analysis of follow-up data in primary breast cancer
    N Harbeck
    Department of Obstetrics and Gynecology, Technical University, Munich, Germany
    Int J Biol Markers 15:116-22. 2000
    ..Nonetheless, the improvement of risk group discrimination represents an important step toward the use of neural networks for decision support in a clinical framework and in making the most of biological markers...
  6. ncbi request reprint Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor
    N Harbeck
    Frauenklinik, Technische Universitat Munchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Onkologie 24:238-44. 2001
    ..Novel therapeutic approaches targeting the PAI-1/uPA interaction are already in pre-clinical testing...
  7. ncbi request reprint Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
    N Harbeck
    Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, D 81675 Munich, Germany
    Clin Cancer Res 7:2757-64. 2001
    ..Prognostic and predictive impact of five proteolytic factors associated with tumor invasion and metastasis in primary breast cancer were evaluated after long-term follow-up...
  8. ncbi request reprint Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination
    Nadia Harbeck
    Clinical Research Group, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    J Clin Oncol 20:1000-7. 2002
    ..The improvement in clinical risk assessment gained by combining these factors is evaluated here...
  9. ncbi request reprint Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
    ....
  10. ncbi request reprint [Adjuvant chemotherapy in primary carcinoma of the breast]
    N Harbeck
    Frauenklinik der Technischen Universitat Munchen, Germany
    Zentralbl Gynakol 125:322-6. 2003
    ..In Germany, up-to-date evidence-based therapy recommendations have just been issued by the AGO "breast" expert panel. Interdisciplinary S3 breast cancer guidelines are currently being finalized...
  11. ncbi request reprint [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]
    N Harbeck
    Frauenklinik der Technischen Universitat Munchen, Germany
    Zentralbl Gynakol 125:362-7. 2003
    ..Moreover, our results suggest the use of novel therapeutic agents interfering with the uPA system together with conventional chemotherapy in patients with high uPA/PAI-1 already in early stage disease...
  12. ncbi request reprint [Adjuvant chemotherapy in primary breast cancer]
    N Harbeck
    Frauenklinik, Klinikum rechts der Isar, Technischen Universität Munich
    Onkologie 26:17-20. 2003
    ..e. NNBC-3, ECDoc, ADEBAR). Up-to-date evidence-based therapy recommendations for adjuvant chemotherapy can be found in the S2 guidelines of the working group on gynecological oncology (AGO) expert panel 'breast' (www.agoonline. de)...
  13. ncbi request reprint Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Thromb Haemost 91:450-6. 2004
    ....
  14. ncbi request reprint Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Clin Breast Cancer 5:348-52. 2004
    ....
  15. pmc The patient experience
    Nadia Harbeck
    Frauenklinik der Technischen Universitat Munchen, Ismaninger Strasse 22, Munich 81675, Germany
    Breast Cancer Res Treat 105:91-103. 2007
    ..The major benefits of letrozole are to improve prospects for long-term survivorship in the adjuvant setting and to delay progression and the need for chemotherapy in the metastatic setting...
  16. ncbi request reprint Never too late: reducing late breast cancer relapse risk
    N Harbeck
    Frauenklinik der Technischen Universitat Munchen, Munchen, Germany
    Curr Med Res Opin 24:3295-305. 2008
    ..Yet, even after the first 5 years, patients with hormone receptor-positive tumours are at risk of relapse. Particularly in endocrine-responsive disease, most instances of relapse and breast cancer mortality occur after the first 5 years...
  17. ncbi request reprint Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
    N Harbeck
    Frauenklinik, Technische Universitat Munchen, Munich, Germany
    Breast Cancer Res Treat 54:147-57. 1999
    ..PAI-1 levels in the primary tumor were also a significant prognostic marker for survival after first relapse in both univariate and multivariate analysis...
  18. ncbi request reprint Prognostic impact of tumor biological factors on survival in node-negative breast cancer
    N Harbeck
    Frauenklinik, Hamburg, Germany
    Anticancer Res 18:2187-97. 1998
    ..1). Thus, factors describing the invasive and metastatic capacity of tumor cells (uPA, PAI-1) and factors related to their proliferative activity (SPF, MIB1) provide valuable prognostic information in node-negative breast cancer patients...
  19. ncbi request reprint Anthracycline and trastuzumab in breast cancer treatment
    M Untch
    Klinikum Grosshadern, Frauenklinik München, Ludwig Maximilians Universitat, Munchen, Germany
    Oncology (Williston Park) 18:59-64. 2004
    ..The interim results of this study approve the cardiac safety of the combination of H with EC, with low risk of cardiac toxicity. The combination regimen revealed promising efficacy...
  20. pmc Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up
    N Harbeck
    Department of Obstetrics and Gynaecology, Klinikum Grosshadern, , Munich, Germany
    Br J Cancer 69:566-71. 1994
    ..In particular, patients with node-negative tumours who have tumour cells in their bone marrow may require subsequent systemic therapy...
  21. ncbi request reprint Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy
    M Schmitt
    Frauenklinik und Poliklinik, Technischen Universitat Munchen, Germany
    Thromb Haemost 78:285-96. 1997
    ....
  22. pmc Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
    N Harbeck
    Frauenklinik, Klinikum rechts der Isar, , Munich, Germany
    Br J Cancer 80:419-26. 1999
    ..001, RR 8.9). In particular, this analysis shows that PAI-1 is still a strong and independent prognostic factor in node-negative breast cancer after extended 6-year median follow-up...
  23. pmc Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer
    M Schmitt
    Frauenklinik und Poliklinik, Munich, Germany
    Br J Cancer 76:306-11. 1997
    ..Evaluation of time dependency of prognostic factors may also give a more profound insight into the dynamics of breast cancer metastasis...
  24. pmc Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
    W Kuhn
    Frauenklinik, , Klinikum rechts der Isar, Germany
    Br J Cancer 79:1746-51. 1999
    ..Even within patient subgroups with or without residual tumour mass, PAI-1 allowed selection of patients at risk who might benefit from individualized therapy protocols...
  25. ncbi request reprint Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
    A Prechtl
    Department of Obstetrics and Gynecology, Technische University, Munich
    Int J Biol Markers 15:73-8. 2000
    ..This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies...
  26. ncbi request reprint Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancer
    D Prechtel
    Institut für allgemeine Pathologie und pathologische Anatomie, Munich, Germany
    Lab Invest 81:159-65. 2001
    ..We conclude that T1-S receptor overexpression is a novel and independent tumor biological factor that may be associated with reduced progression of lymph node-negative breast cancer...
  27. doi request reprint Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3
    M Schmidt
    Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany
    Ann Oncol 20:258-64. 2009
    ..We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification...
  28. doi request reprint Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer
    Thomas Kolben
    Breast Center, Department for Gynecology and Obstetrics and Comprehensive Cancer Center of LMU, University Hospital Munich Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377, Munich, Germany
    Breast Cancer Res Treat 155:109-15. 2016
    ..These findings strongly support the use of uPA/PAI-1 together with clinic-pathological parameters as an evidence-based, clinically relevant and inexpensive decision tool in the routine of a breast center. ..
  29. ncbi request reprint Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer
    N Harbeck
    Technische Universitaet Muenchen, Munich, Germany Department of Medical Biometry, Universitaet Tuebingen, Tuebingen, Germany Department of Obstetrics and Gynecology, Helios Klinikum Berlin Buch, Germany Department of Obstetrics and Gynecology, University of Mainz, Mainz, Germany Universitaetsfrauenklinik Eppendorf, Hamburg, Germany Department of Chemical Endocrinology, University Medical Center Sint Radboud, Nijmegen, Netherlands Department of Obstetrics and Gynecology, Martin Luther University, Halle, Germany
    J Clin Oncol 27:511. 2009
    ....
  30. ncbi request reprint Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratified by HER2-status
    S Paepke
    Technische Universitat Munchen, Munich, Germany Universitätsfrauenklinik Köln, Cologne, Germany Klinikum des Landkreises Deggendorf, Deggendorf, Germany Universitätsfrauenklinik Jena, Jena, Germany
    J Clin Oncol 27:e11512. 2009
    ..Additionally Trans-HEDON includes a translational research program to identify molecular RNA and methylation (DNA) based markers of response to docetaxel-monotherapy...
  31. doi request reprint Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer
    J Dorn
    Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
    Ann Oncol 22:877-83. 2011
    ..The changes in levels of these factors from primary tumor to omentum metastasis ('level differentials') could thus be associated with metastastic processes...
  32. doi request reprint Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival
    J Dorn
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Ann Oncol 22:1783-90. 2011
    ..Kallikrein-related peptidases, including KLK5, have been reported to play an important role in the course of the disease...
  33. ncbi request reprint Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line chemotherapy for metastatic breast cancer (MBC): The PELICAN study
    N Harbeck
    Technical University, Munich, Germany Krankenaus Nordwest, Frankfurt am Main, Germany Dr Horst Schmidt Kliniken, Wiesbaden, Germany Klinikum Offenbach, Offenbach, Germany HELIOS Klinikum Berlin Buch, Berlin, Germany Johannes Gutenberg University, Mainz, Germany
    J Clin Oncol 26:12010. 2008
    ..The phase III PELICAN trial was designed to evaluate efficacy and safety of first-line PLD (50 mg/m2, q28 days) vs. capecitabine (1,250 mg/m2 BID×14 days, q21 days) as approved dose for both agents...
  34. pmc Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer
    P Dettmar
    , Munich, Germany
    Br J Cancer 75:1525-33. 1997
    ..We thus conclude that MIB1-PR and SPF provide additional prognostic information in node-negative breast cancer. However, in our study, flow cytometrically determined SPF had the greater prognostic impact...
  35. doi request reprint Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model
    Michael Patrick Lux
    Universitäts Brustzentrum Franken, Frauenklinik, Universitatsklinikum Erlangen, Universitätsstrasse 21 23, 91054, Erlangen, Germany
    Breast Cancer Res Treat 117:305-17. 2009
    ..A high probability of cost-effectiveness is maintained under variations in all key parameters. The results reflect a tendency for patients receiving fulvestrant at an early stage to maintain high quality of life for a longer interval...
  36. ncbi request reprint Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer
    Iris Zemzoum
    Frauenklinik and Institut für Allgemeine Pathologie und Pathologische Anatomie, Technische Universitat, and Gemeinschaftspraxis Lachnerstrasse 2 für Pathologie und Zytologie, Munchen, Germany
    J Clin Oncol 21:1022-8. 2003
    ....
  37. ncbi request reprint Incremental costs of chemotherapy-Pharmacoeconomic results from the prospective adjuvant AGO-WSG intergroup EC->DOC trial comparing an anthracycline-docetaxel sequence to CMF in node-positive breast cancer
    V R Jacobs
    Klinikum rechts der Isar der TU Munchen, Munich, Germany University Bonn, Bonn, Germany Klinukum rechts der Isar der TU München, Munich, Germany Gynecology Arabella, Munich, Germany
    J Clin Oncol 26:583. 2008
    ....
  38. ncbi request reprint Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow
    C Schindlbeck
    I Frauenklinik, Klinikum Ludwig Maximilians University, Munich, Germany
    Breast Cancer Res Treat 87:65-74. 2004
    ..The direct identification of HER2 on ITC-BM is the aim of ongoing research, potentially synergizing the prognostic relevance of ITC-BM and the predictive value of the HER2 status...
  39. ncbi request reprint Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Clin Breast Cancer 3:196-200. 2002
    ..Thus, combined determination of the invasion factors uPA and PAI-1 supports risk-adapted individualized therapeutic strategies in patients with primary breast cancer, particularly in those with node-negative breast cancer...
  40. ncbi request reprint Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Crit Rev Clin Lab Sci 44:179-201. 2007
    ..This concept could be useful in assessing and maximizing the performance of risk assessment and the quality of therapeutic indications...
  41. ncbi request reprint Patient's Anastrozole Compliance to Therapy Programme (PACT): Influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early-stage breast cancer
    P Hadjii
    Johannes Gutenberg University Mainz, Mainz, Germany Brustkrebs Deutschland e V, Munchen, Germany TU München, Munchen, Germany Klinikum Offenbach, Offenbach, Germany Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany Breast Health, Bewusst Handeln Gegen Brustkrebs, Hamburg, Germany Rexrodt von Fircks Stiftung, Ratingen, Germany AstraZeneca GmbH Wedel, Wedel, Germany University of Ulm, Ulm, Germany
    J Clin Oncol 26:11582. 2008
    ..To date, no data on compliance to aromatase inhibitors (AI) outside of randomized clinical trials (RCTs) has been reported...
  42. ncbi request reprint ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial
    C Thomssen
    Martin Luther University Halle Wittenberg, Halle, Germany Johannes Gutenberg Universitaet, Mainz, Germany Centre Henri Becquerel, Rouen, France Eberhard Karls University, Tuebingen, Germany German Breast Group GmbH GBG, Neu Isenburg, Germany l AP HM, Marseille, France University Medical Center, Nijmegen, Netherlands Technische Universitaet, Munich, Germany
    J Clin Oncol 27:544. 2009
    ..standard FEC*6...
  43. ncbi request reprint Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and T
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Int J Oncol 25:1397-406. 2004
    ..With this approach, a major step forward in the knowledge and understanding of the biological role and the clinical utility of tumor-associated biomarkers would be anticipated...
  44. ncbi request reprint Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update
    Stefan Paepke
    Frauenklinik des Universitätsklinikums rechts der Isar, Technische Universitat Munchen, Germany
    Onkologie 29:210-7. 2006
    ....
  45. ncbi request reprint FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
    Christoph Thussbas
    Department of Obstetrics and Gynecology, Institute of Pathology, and Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany
    J Clin Oncol 24:3747-55. 2006
    ..5 months)...
  46. ncbi request reprint Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels
    Razvan T Radulescu
    Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munchen, Germany
    Int J Oncol 30:73-80. 2007
    ..Our present report should also provide an experimental starting point towards exploring a potential role of IDE in the control of tumor progression...
  47. ncbi request reprint European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Eur J Cancer 43:835-44. 2007
    ..The resulting tissue cell debris sediment is a rich source of genomic DNA...
  48. ncbi request reprint Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching
    Stefan Paepke
    Interdisciplinary Breast Center, Operative Senology, Frauenklinik OB GYN, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    J Cancer Res Clin Oncol 133:905-16. 2007
    ....
  49. doi request reprint Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy
    Katja Specht
    Institute of Pathology, Technical University Munich, Ismaningerstrasse 22, 81675, Munich, Germany
    Breast Cancer Res Treat 118:45-56. 2009
    ..Whether the biomarker profile is chemotherapy-specific or whether it is a more general indicator of bad prognosis of breast cancer patients remains to be explored...
  50. doi request reprint Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
    Manfred Schmitt
    Frauenklinik der Technischen Universitaet Muenchen, Germany
    Expert Rev Mol Diagn 10:1051-67. 2010
    ..Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas...
  51. ncbi request reprint Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1-3 positive lymph nodes
    U Nitz
    West German Study Group, Moenchengladbach, Germany University Hospital, Tuebingen, Germany University Hospital, Hamburg, Germany University Hospital, Munich, Germany Protestant Hospital, Oberhausen, Germany City Hospital Hoechst, Frankfurt, Germany St Josef Hospital, Wiesbaden, Germany City Hospital, Deggendorf, Germany City Hospital, Boeblingen, Germany University Hospital, Bonn, Germany
    J Clin Oncol 26:515. 2008
    ..Subgroup analyses from several trials indicate that patients with 1 to 3 positive nodes, though at intermediate risk, will have a maximum benefit from taxane-based therapy...
  52. doi request reprint Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution
    S Corradini
    Department of Radiation Oncology, University of Munich, Marchioninistr 15, 81377, Munich, Germany
    Strahlenther Onkol 190:352-7. 2014
    ..This retrospective clinical cohort study was performed to investigate the impact of a delay in surgery-radiotherapy intervals on local control and overall survival...
  53. ncbi request reprint Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial
    M Untch
    Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde, Ludwig Maximilians Universitat, Munchen, Germany
    Eur J Cancer 40:988-97. 2004
    ..Objective response rates with EC60+H and EC90+H were >60%, and 26% for EC90 alone. These results indicate that trastuzumab may be combined with EC with manageable cardiotoxicity and promising efficacy...
  54. ncbi request reprint Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis
    A Kruger
    Klinische Forschergruppe der Frauenklinik, Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München, Munich, Germany
    Cancer Res 61:1272-5. 2001
    ..Induction of organ-specific side effects need to be taken into account regarding further development and clinical use of synthetic MMP inhibitors...
  55. pmc Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients
    S Braun
    Department of Obstetrics and Gynecology, Clinical Research Unit, Technical University, Munich, Germany
    Breast Cancer Res 3:285-8. 2001
    ..Standardized and robust methodology is a prerequisite for clinical application of these techniques, however...
  56. ncbi request reprint Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours
    B Muehlenweg
    Wilex AG, Clinical Research Unit, Department of Obstetrics and Gynaecology, Technical University of Munich, D-81675 Munich, Germany
    Expert Opin Biol Ther 1:683-91. 2001
    ....
  57. ncbi request reprint Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer
    S Braun
    Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Semin Surg Oncol 20:334-46. 2001
    ..The present review summarises the current data on the clinical significance of occult metastatic cancer cells in bone marrow...
  58. ncbi request reprint Advanced statistical methods for the definition of new staging models
    Ronald Kates
    Klinische Forschergruppe der Frauenklinik, Technische Universitat Munchen, Ismaningerstr 22, 81675 Munich, Germany
    Recent Results Cancer Res 162:101-13. 2003
    ..In this article, advantages of advanced statistical methods such as neural networks for definition of new staging models will be illustrated using breast cancer as an example...
  59. doi request reprint Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker
    Ariane Sadr-Nabavi
    Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
    Int J Cancer 124:1727-35. 2009
    ..Furthermore, these data point towards a possible predictive impact of EFEMP1 expression in primary breast cancer...
  60. ncbi request reprint CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy
    F Noack
    Klinische Forschergruppe der Frauenklinik, Klinikum rechts der Isar, Technische Universitat Munchen, D 81675 Munchen, Germany
    Int J Oncol 15:617-23. 1999
    ..CD87-positive tumor cells were also dissected from stained bone marrow aspirates by laser microdissection microscope to allow analysis of single cells at the gene level...
  61. pmc Treatment planning and evaluation of gated radiotherapy in left-sided breast cancer patients using the CatalystTM/SentinelTM system for deep inspiration breath-hold (DIBH)
    S Schönecker
    Department of Radiation Oncology, LMU University, Marchioninistrase 15, 81377, Munich, Germany
    Radiat Oncol 11:143. 2016
    ....
  62. ncbi request reprint Results of the German IPEP study evaluating tolerability, efficacy and acceptance of fulvestrant under routine clinical conditions in advanced breast cancer
    M Warm
    Uniklinik Cologne, Cologne, Germany Charité Berlin, Berlin, Germany TU München, Munchen, Germany
    J Clin Oncol 26:1092. 2008
    ..The questions of the study are whether fulvestrant is safe, effective and tolerable...
  63. ncbi request reprint Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC)
    H Stemmler
    University of Munich, Klinikum Grosshadern, Munich, Germany Technical University, Klinikum rechts der Isar, Munich, Germany Klinikum Ebersberg, Ebersberg, Germany Onkologische Praxis, Landshut, Germany Schlossbergklinik Oberstaufen, Oberstaufen, Germany Onkologische Praxis, Munich, Germany University of Munich, Klinikum Innenstadt, Munich, Germany St Vincentius Kliniken, Karlsruhe, Germany
    J Clin Oncol 27:1101. 2009
    ..1101 Background: We investigated the toxicity and efficacy of weekly applied docetaxel compared to its standard 3-weekly application in pts previously untreated with chemotherapy for MBC...
  64. ncbi request reprint Interim safety analysis of the randomized phase III PELICAN trial evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line therapy for metastatic breast cancer
    S al-Batran
    Rechts der Isar, Technische Universitat Muenchen, Munich, Germany Krankenhaus Nordwest, Frankfurt am Main, Germany Rechts der Isar, TU Muenchen, Munich, Germany Klinikum der Johannes Gutenberg Universität, Mainz, Germany Universitätsfrauenklinik, Ulm, Germany Onkologische Schwerpunktpraxis, Oldenburg, Germany Brustzentrum Universität Köln, Koln, Germany Essex Pharma, Munich, Germany Heliosklinikum Berlin Buch, Berlin, Germany
    J Clin Oncol 27:1118. 2009
    ..The PELICAN trial was designed to evaluate efficacy and safety of first-line PLD vs capecitabine at standard approved dosages...
  65. ncbi request reprint First data from the the Patient's Anastrozole Compliance to Therapy Programme evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer
    C Jackisch
    Klinikum Offenbach, Offenbach, Germany TU München, Munchen, Germany Johannes Gutenberg University, Mainz, Germany Philipps University, Marburg, Germany Gyn Onkol Praxis, Hannover, Germany Mamazone Frauen und Forschung, Augsburg, Germany Brustkrebs Deutschland e V, Munchen, Germany AstraZeneca GmbH, Wedel, Germany University of Ulm, Ulm, Germany
    J Clin Oncol 27:e11592. 2009
    ..Little is known about compliance to AI and patient motivation outside of clinical trials and the effect of compliance on patient outcome...
  66. ncbi request reprint Counseling and care: A Breast Cancer Awareness Training to improve participation and adherence to screening recommendations in women with a family history of breast cancer
    A Artmann
    Klinikum r d Isar, TU Munich, Munich, Germany
    J Clin Oncol 27:1530. 2009
    ..The aim of this investigation was to evaluate the impact of an indivualized Breast Cancer Awareness Training to improve the participation and adherence towards an ISP...
  67. ncbi request reprint Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis
    G von Minckwitz
    German Breast Group, Neu Isenburg, Germany University Hospital, Frankfurt, Germany Breast Unit, Cancer Center Essen, Essen, Germany Frauenklinik des Universitätsklinikums Erlangen, Erlangen, Germany Klinikum zum Roten Kreuz, Muenchen, Germany Brustzentrum Sankt Gertrauden Krankenhaus, Berlin, Germany Universitaets Frauenklinik, Magdeburg, Germany Henrietten Stiftung, Hannover, Hannover, Germany Klinikum Offenbach, Offenbach, Germany Universitäts Frauenklinik, Rostock, Germany Kliniken Essen Mitte, Essen, Germany University of Tuebingen and Kantonsspital St Gallen, St Gallen, Switzerland Rot Kreuz Klinikum München, Munich, Germany University of California, Los Angeles, Los Angeles, CA Haemato Onkologische Praxis, Wuppertal, Germany University of Freiburg, Freiburg, Germany West German Study Group and University of Cologne, Cologne, Germany HELIOS Klinikum Berlin Buch, Berlin, Germany
    J Clin Oncol 29:1028. 2011
    ..We therefore correlated pCR and survival using our meta-database of 7 German neoadjuvant trials using anthracyclines, taxanes regimen with or without trastuzumab...
  68. ncbi request reprint Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b
    A Schnelzer
    Department of Obstetrics and Gynecology, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaninger Str 22, 0 81675 Munich, Germany
    Oncogene 19:3013-20. 2000
    ..In addition, breast tumor cells from patients with recurrent disease had Rac1 expression at the plasma membrane, suggesting activation of Rac1, in patients with aggressive breast cancer. Oncogene (2000)...
  69. ncbi request reprint Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
    K Lindemann
    Department of Obstetrics and Gynaecology, Technical University, Munich, Germany
    Histopathology 51:54-62. 2007
    ....
  70. doi request reprint Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy
    N Harbeck
    Department of Oncology, Breast Center, Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany
    Ann Oncol 22:1250-8. 2011
    ..Since adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life...
  71. ncbi request reprint G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients
    Janna Krol
    Frauenklinik der Technischen Universitat Munchen, Klinikum rechts der Isar, Munich, Germany
    Onkologie 29:171-8. 2006
    ..This article reviews and summarizes cutting-edge, disease-specific data as well as national and international guidelines regarding the use of G-CSFs to prevent chemotherapy-induced FN, with focus on the treatment of breast cancer...
  72. ncbi request reprint Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients
    Julia Dorn
    Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Clin Cancer Res 13:1742-8. 2007
    ....
  73. doi request reprint Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report
    Hans Joachim Stemmler
    Medical Department III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, Munich, Germany
    Anticancer Drugs 19:832-6. 2008
    ..This case report gives details regarding the clinical course of a breast cancer patient who received intrathecal trastuzumab and methotrexate via lumbar puncture for meningeal carcinomatosis of HER2-overexpressing MBC...
  74. pmc Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Sibylle Loibl
    Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res 10:R77. 2008
    ..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients...
  75. doi request reprint Gustatory and olfactory function in breast cancer patients
    Silke Steinbach
    Department of Otorhinolaryngology, Technical University, Dresden, Germany
    Support Care Cancer 18:707-13. 2010
    ..This knowledge would be important for adequate patient counseling as well as symptom relief. Several studies investigated taste function, but to our knowledge, only one studied olfactory function in cancer patients...
  76. ncbi request reprint Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention
    S Braun
    Frauenklinik und Poliklinik, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaninger Strasse 22, D 81675 Munchen, Germany
    Expert Rev Mol Med 3:1-14. 2001
    ..This review summarises current data on the clinical significance of occult metastatic breast cancer cells in bone marrow...
  77. ncbi request reprint Incorporation of a Comprehensive Geriatric Assessment (CGA) into a randomized phase III trial for metastatic breast cancer: The PELICAN Study
    M de Wit
    Vivantes Klinikum Neukölln, Berlin, Germany Munich Technical University, Munich, Germany Trium Analysis, Munich, Germany Essex Pharma, Munich, Germany University Hospital Jena, Jena, Germany University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 27:9551. 2009
    ..Randomisation was stratified according to age (cut-off 65 years) and anthracycline pretreatment. CGA results and adverse events (AEs), dose reductions, and number of applied cycles were evaluated...
  78. ncbi request reprint Prospective study comparing hospital costs and DRG reimbursement of inpatient treatment of febrile neutropenia during adjuvant anthracycline-based CTX for primary breast cancer
    V R Jacobs
    Technical University Munich, Munich, Germany
    J Clin Oncol 27:e11570. 2009
    ..To date limited data on costs of FN management is available. We compared costs and reimbursement of FN in a study of BC patients during adjuvant anthracycline (AC)-based CTX...
  79. ncbi request reprint Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial
    J W Janni
    HHU, Duesseldorf, Germany University Dusseldorf, Duesseldorf, Germany Department of Gynecology and Obstetrics, Klinikum der Ludwig Maximilians Universität, Munich, Germany West German Study Group and University of Cologne, Cologne, Germany Department of Gynecology and Obstetrics, Klinikum der Ludwig Maximilians Universita, Munich, Germany Department of Gynecology and Obstetrics, Klinikum der Ludwig Maximilians Universitaet, Munich, Germany Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany Zentraklinikum, Augsburg, Germany Robert Bosch Krankenhaus, Stuttgart, Germany Breast Center Düsseldorf, Dusseldorf, Germany Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany National Center for Tumor Diseases, Heidelberg, Germany Frauenklinik des Universitätsklinikums Erlangen, Erlangen, Germany Universitäts Frauenklinik, Rostock, Germany Estimate, Augsburg, Germany Klinikum der Ludwig Maximilians Universität, Munich, Germany
    J Clin Oncol 29:1020. 2011
    ..This analysis focuses on the impact of obesity on high risk BC patients (pts) treated within the ADEBAR study protocol...
  80. ncbi request reprint Antibody therapy for breast cancer
    Amina Willems
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Anticancer Res 25:1483-9. 2005
    ..It binds to a different epitope on HER2/neu than trastuzumab and inhibits heterodimerization with other HER receptors. Phase I data showed that 2C4 is well tolerated and clinically active...
  81. ncbi request reprint Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care
    Volker R Jacobs
    Oberarzt Forschung und Klinikmanagement, Frauenklinik, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Onkologie 28:441-5. 2005
    ..Although developed for optimization of cost coverage of oncological therapies in Germany, this model is universally transferable...
  82. doi request reprint Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET
    Ambros J Beer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 49:255-9. 2008
    ..The integrin alpha(v)beta(3) is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the alpha(v)beta(3)-selective PET tracer (18)F-galacto-RGD in invasive ductal breast cancer...
  83. ncbi request reprint Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance
    Frigga Roggel
    Klinische Forschergruppe der Frauenklinik, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
    Recent Results Cancer Res 162:89-100. 2003
    ....
  84. ncbi request reprint Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
    Hans Joachim Stemmler
    Medical Department III, Ludwig Maximilians University of Munich, Clinic Grosshadern, Munich, Germany
    Anticancer Drugs 18:23-8. 2007
    ....
  85. doi request reprint Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies
    Silke Steinbach
    Smell and Taste Clinic, Department of Otorhinolaryngology, Technical University, Dresden, Dresden, Germany
    J Clin Oncol 27:1899-905. 2009
    ..This prospective study comprehensively investigated, to our knowledge for the first time, smell and taste changes in a cohort of 87 patients undergoing chemotherapy for breast cancer or gynecologic malignancies...
  86. doi request reprint Angiogenesis inhibitors in the management of breast cancer
    Verena Bossung
    Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany
    Curr Opin Obstet Gynecol 22:79-86. 2010
    ..This review highlights therapeutic agents from recent breast cancer trials showing the greatest potential for further clinical use in the near future...
  87. ncbi request reprint Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1
    Martin Janz
    Department of Cell Growth and Differentiation, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Int J Cancer 97:278-82. 2002
    ....
  88. ncbi request reprint Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  89. ncbi request reprint [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)]
    Nadia Harbeck
    MMW Fortschr Med 145:8, 10. 2003
  90. ncbi request reprint Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients
    Maxime Look
    Erasmus MC, Josephine Nefkens Institute, Rm Be 428, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Thromb Haemost 90:538-48. 2003
    ..We conclude that uPA and PAI-1 are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups...
  91. ncbi request reprint Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker
    Andreas Scorilas
    Department of Biochemistry and Molecular Biology, University of Athens, Greece
    J Clin Oncol 22:678-85. 2004
    ..We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas...
  92. ncbi request reprint Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
    ..Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system...
  93. ncbi request reprint C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
    Ernst Lengyel
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Mail Code 2050, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Int J Cancer 113:678-82. 2005
    ..In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients...
  94. ncbi request reprint Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
    ..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer...
  95. ncbi request reprint Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 24:1665-71. 2006
    ..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions...
  96. ncbi request reprint Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 12:1487-93. 2006
    ..001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer...
  97. ncbi request reprint The role of capecitabine in first-line treatment for patients with metastatic breast cancer
    Karen Gelmon
    British Columbia Cancer Agency, Vancouver, Canada
    Oncologist 11:42-51. 2006
    ..Recently, clinical trials have studied single-agent capecitabine as first-line treatment and evaluated other capecitabine-containing combinations with cytotoxic and novel targeted agents...
  98. ncbi request reprint 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  99. ncbi request reprint Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer
    Mathias Warm
    Department of Senology, University of Cologne, Germany
    Anticancer Res 27:1031-8. 2007
    ....
  100. ncbi request reprint DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration wit
    Sabine Maier
    Department of Research, Epigenomics AG, Berlin, Germany
    Eur J Cancer 43:1679-86. 2007
    ..In addition, these low-risk postmenopausal patients seem to respond sufficiently well to tamoxifen so that they may not require up-front aromatase inhibitor therapy...
  101. ncbi request reprint Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer
    Mathias Warm
    Department of Senology, University of Cologne, Germany
    Onkologie 30:436-41. 2007
    ..This is a retrospective cohort study on the safety and efficacy profiles of weekly docetaxel at varying doses in patients with pretreated metastatic breast cancer...